サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1469861

希少疾病用医薬品の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）

Global Orphan Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
希少疾病用医薬品の世界市場：産業分析、規模、シェア、成長、動向、予測（2024～2032年）
出版日: 2024年04月01日
発行: Value Market Research
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の希少疾病用医薬品の市場規模は、2023年に1,949億5,000万米ドルに達し、2024～2032年の予測期間中にCAGR 7.12%で成長し、2032年には約3,620億4,000万米ドルに達すると予測されています。

希少疾病用医薬品とは、少数の患者にしか影響を与えない希少な疾患や病態を治療するために開発された医薬品です。製薬企業は、患者数が限られていることや医薬品開発・商業化の課題から、これらの疾患により多くの注意を払う必要があります。これらの医薬品は、特許保護期間の延長、税額控除、承認プロセスの迅速化など、規制当局による特別な優遇措置や市場独占権を得て、その成長を促しています。

市場力学

希少疾患や障害の有病率の増加、遺伝子研究や診断技術の進歩が、特定の遺伝子変異や希少疾患をターゲットとする希少疾病用医薬品の需要を牽引しています。さらに、米国の希少疾病用医薬品法（Orphan Drug Act）や他国の同様の規制など、保健当局による規制上の優遇措置や希少疾病用医薬品の指定が、製薬企業による希少疾病用医薬品の研究開発への投資を後押ししています。さらに、希少疾患の患者擁護団体や支援団体の増加により、希少疾患治療薬に対する意識が高まり、希少疾患治療薬へのアクセスが擁護されているため、需要が高まり、市場の成長が促進されています。さらに、遺伝子治療、細胞治療、精密医療アプローチなどのバイオテクノロジーや医薬品開発技術の進歩により、有効性と安全性が向上した革新的な希少疾病用治療薬の開発が可能となっています。

さらに、希少疾病用医薬品治療に対する医療費と保険適用の増加、個別化医療と価値に基づく医療モデルの受容の高まりが、希少疾病用医薬品メーカーにとって有利な市場条件を生み出しています。さらに、製薬企業、学術機関、研究機関の戦略的提携や協力関係がイノベーションを促進し、希少疾病用医薬品の開発と商業化を加速させています。しかし、代替療法との競合の激化や患者アクセスの制限により、今後数年間は希少疾病用医薬品市場の成長が課題となる可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、産業の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは希少疾病用医薬品の世界市場における各セグメントを包括的に評価することもできます。希少疾病用医薬品産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

市場セグメンテーションでは、国・地域レベルのセグメントに関する詳細なデータを提供することで、戦略担当者が各製品・サービスのターゲット層を特定し、今後のビジネスチャンスに役立てることができます。

疾患タイプ別

  • 腫瘍
  • 消化器
  • 呼吸器
  • 神経学
  • 血液学
  • 循環器
  • 代謝疾患
  • 内分泌学
  • 感染症
  • その他

指標別

  • 生物学的
  • 非生物学的

流通チャネル別

  • 病院薬局
  • 専門薬局
  • 小売薬局
  • その他

地域別分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける希少疾病用医薬品市場の現在および将来の需要について、地域別の展望を取り上げます。さらに、すべての主要地域における各用途セグメントの需要・推定・予測にも焦点を当てています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 希少疾病用医薬品 - 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 希少疾病用医薬品の世界市場分析：疾患タイプ別

  • 概要：疾患タイプ別
  • 実績データと予測データ
  • 分析：疾患タイプ別
  • 腫瘍
  • 消化器
  • 呼吸器
  • 神経学
  • 血液学
  • 循環器
  • 代謝疾患
  • 内分泌学
  • 感染症
  • その他

第6章 希少疾病用医薬品の世界市場分析：指標別

  • 概要：指標別
  • 実績データと予測データ
  • 分析：指標別
  • 生物学的
  • 非生物学的

第7章 希少疾病用医薬品の世界市場分析：流通チャネル別

  • 概要：流通チャネル別
  • 実績データと予測データ
  • 分析：流通チャネル別
  • 病院薬局
  • 専門薬局
  • 小売薬局
  • その他

第8章 希少疾病用医薬品の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋地売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第9章 希少疾病用医薬品企業の競合情勢

  • 希少疾病用医薬品市場の競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Alexion Pharmaceuticals Inc.
  • Eli Lilly And Company
  • Novo Nordisk A/S
  • AstraZeneca Plc
  • Eisai Co. Ltd.
  • Daiichi Sankyo Company Limited
  • Bayer AG
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Johnson & Johnson
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Disease Type (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Gastrointestinal Market Sales By Geography (USD MN)
  • Pulmonary Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Hematology Market Sales By Geography (USD MN)
  • Cardiovascular Market Sales By Geography (USD MN)
  • Metabolic Disorders Market Sales By Geography (USD MN)
  • Endocrinology Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Indicator (USD MN)
  • Biologic Market Sales By Geography (USD MN)
  • Non-biologic Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Specialty Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Orphan Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Orphan Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Orphan Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By Indicator
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Disease Type (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Gastrointestinal Market Sales By Geography (USD MN)
  • Pulmonary Market Sales By Geography (USD MN)
  • Neurology Market Sales By Geography (USD MN)
  • Hematology Market Sales By Geography (USD MN)
  • Cardiovascular Market Sales By Geography (USD MN)
  • Metabolic Disorders Market Sales By Geography (USD MN)
  • Endocrinology Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Indicator (USD MN)
  • Biologic Market Sales By Geography (USD MN)
  • Non-biologic Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Specialty Pharmacies Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114268

The global demand for Orphan Drugs Market is presumed to reach the market size of nearly USD 362.04 Billion by 2032 from USD 194.95 Billion in 2023 with a CAGR of 7.12% under the study period 2024 - 2032.

Orphan drugs are pharmaceutical medications created to treat rare diseases or conditions impacting a small number of individuals. Pharmaceutical companies often need to pay more attention to these diseases due to their limited patient populations and drug development and commercialization challenges. These drugs, including extended patent protection, tax credits, and accelerated approval processes, receive special regulatory incentives and market exclusivity to encourage their growth.

MARKET DYNAMICS

The increasing prevalence of rare diseases and disorders and advances in genetic research and diagnostic technologies drive the demand for orphan drugs targeting specific genetic mutations or rare conditions. Additionally, regulatory incentives and orphan drug designations granted by health authorities, such as the Orphan Drug Act in the United States and similar regulations in other countries, encourage pharmaceutical companies to invest in the research and development of orphan drugs. Furthermore, the growing patient advocacy and support groups for rare diseases are raising awareness and advocating for access to orphan drugs, driving demand and facilitating market growth. Moreover, advancements in biotechnology and drug development techniques, such as gene therapy, cell therapy, and precision medicine approaches, enable the development of innovative orphan drug therapies with improved efficacy and safety profiles.

Additionally, the increasing healthcare expenditure and insurance coverage for orphan drug treatments, combined with the growing acceptance of personalized medicine and value-based healthcare models, create favorable market conditions for orphan drug manufacturers. Furthermore, strategic collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations foster innovation and accelerate the development and commercialization of orphan drugs. However, increasing competition from alternative therapies and limited patient access may challenge the growth of the orphan drugs market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of orphan drugs. The growth and trends of orphan drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the orphan drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

  • Oncology
  • Gastrointestinal
  • Pulmonary
  • Neurology
  • Hematology
  • Cardiovascular
  • Metabolic Disorders
  • Endocrinology
  • Infectious Diseases
  • Others

By Indicator

  • Biologic
  • Non-Biologic

By Distribution Channel

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Orphan Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Orphan Drugs market include Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Sanofi S.A., Alexion Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, AstraZeneca plc, Eisai Co., Ltd., Daiichi Sankyo Company Limited, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ORPHAN DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Disease Type
    • 3.7.2 Market Attractiveness Analysis By Indicator
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISEASE TYPE

  • 5.1. Overview By Disease Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Disease Type
  • 5.4. Oncology Historic and Forecast Sales By Regions
  • 5.5. Gastrointestinal Historic and Forecast Sales By Regions
  • 5.6. Pulmonary Historic and Forecast Sales By Regions
  • 5.7. Neurology Historic and Forecast Sales By Regions
  • 5.8. Hematology Historic and Forecast Sales By Regions
  • 5.9. Cardiovascular Historic and Forecast Sales By Regions
  • 5.10. Metabolic Disorders Historic and Forecast Sales By Regions
  • 5.11. Endocrinology Historic and Forecast Sales By Regions
  • 5.12. Infectious Diseases Historic and Forecast Sales By Regions
  • 5.13. Others Historic and Forecast Sales By Regions

6. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY INDICATOR

  • 6.1. Overview By Indicator
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Indicator
  • 6.4. Biologic Historic and Forecast Sales By Regions
  • 6.5. Non-biologic Historic and Forecast Sales By Regions

7. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Distribution Channel
  • 7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 7.5. Specialty Pharmacies Historic and Forecast Sales By Regions
  • 7.6. Retail Pharmacies Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ORPHAN DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ORPHAN DRUGS COMPANIES

  • 9.1. Orphan Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF ORPHAN DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Novartis AG
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Bristol-Myers Squibb Company
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Celgene Corporation
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. F. Hoffmann-La Roche Ltd.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Pfizer Inc.
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Sanofi S.A.
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Alexion Pharmaceuticals Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Eli Lilly And Company
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. Novo Nordisk A/S
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. AstraZeneca Plc
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Eisai Co. Ltd.
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Daiichi Sankyo Company Limited
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Bayer AG
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. GlaxoSmithKline Plc
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Merck & Co. Inc.
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments
  • 10.18. Johnson & Johnson
    • 10.18.1 Company Overview
    • 10.18.2 Company Revenue
    • 10.18.3 Products
    • 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies